// App-Quantinova.ai

PO‐064 : Development of an Idelalisib safety monitoring tool

Researchers

Presenter

  • R Hinton

Principal Investigators

  • J Norman

Medical Centers

  • Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Tumor protein p53

Drug/Treatment

  • Idelalisib

  • Rituximab

  • Methadone hydrochloride

  • TP53

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved